AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 293: E849-E856, 2007. First published July 3, 2007; doi:10.1152/ajpendo.00289.2007
0193-1849/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/3/E849    most recent
00289.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meier, J. J.
Right arrow Articles by Nauck, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meier, J. J.
Right arrow Articles by Nauck, M. A.

Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans

Juris J. Meier,1 Jens J. Holst,2 Wolfgang E. Schmidt,1 and Michael A. Nauck3

1Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany; 2Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen Denmark; and 3Diabeteszentrum Bad Lauterberg, Lauterberg, Germany

Submitted 10 May 2007 ; accepted in final form 29 June 2007

Changes in hepatic insulin clearance can occur after oral glucose or meal ingestion. This has been attributed to the secretion and action of gastric inhibitory polypeptide (GIP) and glucagon-like peptide (GLP)–1. Given the recent availability of drugs based on incretin hormones, such clearance effects may be important for the future treatment of type 2 diabetes. Therefore, we determined insulin clearance in response to endogenously secreted and exogenously administered GIP and GLP-1. Insulin clearance was estimated from the molar C-peptide-to-insulin ratio calculated at basal conditions and from the respective areas under the curve after glucose, GIP, or GLP-1 administration. Oral glucose administration led to an ~60% reduction in the C-peptide-to-insulin ratio (P < 0.0001), whereas intravenous glucose administration had no effect (P = 0.09). The endogenous secretion of GIP or GLP-1 was unrelated to the changes in insulin clearance. The C-peptide-to-insulin ratio was unchanged after the intravenous administration of GIP or GLP-1 in the fasting state (P = 0.27 and P = 0.35, respectively). Likewise, infusing GLP-1 during a meal course did not alter insulin clearance (P = 0.87). An inverse nonlinear relationship was found between the C-peptide-to-insulin ratio and the integrated insulin levels after oral and during intravenous glucose administration. Insulin clearance is reduced by oral but not by intravenous glucose administration. Neither GIP nor GLP-1 has significant effects on insulin extraction. An inverse relationship between insulin concentrations and insulin clearance suggests that the secretion of insulin itself determines the rate of hepatic insulin clearance.

homeostasis model assessment; microparticle enzyme immunoassay



Address for reprint requests and other correspondence: J. J. Meier, Dept. of Medicine I, St. Josef-Hospital, Ruhr-Univ. of Bochum, Gudrunstr. 56, 44791 Bochum, Germany (e-mail: juris.meier{at}rub.de)




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Campioni, G. Toffolo, R. Basu, R. A. Rizza, and C. Cobelli
Minimal model assessment of hepatic insulin extraction during an oral test from standard insulin kinetic parameters
Am J Physiol Endocrinol Metab, October 1, 2009; 297(4): E941 - E948.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
D. S. Edgerton, K. M.S. Johnson, D. W. Neal, M. Scott, C. H. Hobbs, X. Zhang, A. Duttaroy, and A. D. Cherrington
Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
Diabetes, January 1, 2009; 58(1): 243 - 249.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.